Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.
Vida TerzićJoe Miantezila BasiluaNicolas BillardLucie de GastinesDrifa BelhadiClaire Fougerou-LeurentNathan Peiffer SmadjaNoémie MercierChristelle DelmasAssia FerraneAline DechanetJulien PoissyHélène EspérouFlorence AderMaya HitesClaire AndrejakRichard GreilJosé-Artur PaivaThérèse StaubEvelina TacconelliCharles BurdetDominique CostagliolaFrance MentréYazdan YazdanpanahAlpha Diallonull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Remdesivir treatment was not associated with an increased risk of cardiac AEs, whether serious or not, and regardless of AE severity, compared to control, in patients hospitalized with moderate or severe COVID-19. This is consistent with the results of other randomized controlled trials and meta-analyses.
Keyphrases
- coronavirus disease
- meta analyses
- sars cov
- phase iii
- end stage renal disease
- randomized controlled trial
- left ventricular
- systematic review
- respiratory syndrome coronavirus
- newly diagnosed
- phase ii
- clinical trial
- open label
- double blind
- peritoneal dialysis
- study protocol
- prognostic factors
- high throughput
- early onset
- heart failure
- atrial fibrillation
- drug induced
- smoking cessation